Previous 10 | Next 10 |
Palm Beach, FL – May 20, 2021 – In the race against emerging coronavirus variants, researchers are looking beyond antibodies for clues to lasting protection from COVID-19. Concerns about coronavirus variants that might be partially resistant to antibody defenses have spurred r...
SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20, 2021, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live...
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announces that the European Medicines Agency ((EMA)) has started a rolling review of data on sotrovimab (previously VIR-7831), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents with COVI...
– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 – – Review will support a formal Marketing Authorization Application – ȁ...
Vir Biotechnology (VIR) posted a wider first-quarter loss, partly due to an increase in research and development expenses during the period.The company's research and development expenses were $134.9M for the quarter ended March 31 compared to $65M in the same period last year. Net loss ...
Vir Biotechnology (VIR): Q1 GAAP EPS of -$1.32 misses by $1.31.Revenue of $2M (-65.0% Y/Y) misses by $96.64M.As of March 31, 2021, excluding restricted cash, the company had about $733M in cash, cash equivalents and investments.Press Release For further details see: Vir Biotechnology EP...
SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. “We’ve had an active start to the year, achieving significant clinical and c...
Though the pair in a statement assured the public that they will continue to work together at their foundation despite ending their marriage, the news about the Microsoft (MSFT) founder and his partner of 27 years may send shockwaves across their projects.In the latest 13F filing from the Bil...
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021. The update will be provided via a press...
Shares of Vir Biotechnology remain a dangerous play for bulls and bears alike. The highly volatile clinical-stage biotech company has posted the majority of its gains on single-day spikes. Long or short exposure is unsafe with near-term catalysts limited to likely 'priced in' news...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...